Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 and Auto-HSCT for B-Cell Malignancies MRD
NCT03685786Phase 1Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ARI-0001 in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and B cell lymphoma, sponsored by Shenzhen Second People's Hospital. Primary endpoint: CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT at 28 days. Status: unknown.
02
Drugs
ARI-0001
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT03685786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685786.